ArticleCureus2026
Cutaneous Fusariosis in a Pediatric Patient With Leukemia: A Diagnostic and Therapeutic Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusariosis is a rare opportunistic fungal infection that primarily affects immunocompromised patients. Due to its nonspecific initial clinical manifestations, diagnosis is often delayed, which has a negative impact on patient outcomes. We report the case of an eight-year-old male patient with relapsed acute B-cell lymphoblastic leukemia and central nervous system involvement who developed fever and neutropenia during chemotherapy. Even though treatment with broad-spectrum antibiotic therapy was initiated, the patient developed disseminated cutaneous lesions characterized by erythematous macules that later progressed to necrotic plaques. Antifungal therapy with amphotericin B and voriconazole was established, but the patient's clinical condition deteriorated rapidly, resulting in septic shock and a fatal outcome. Histopathological examination and fungal cultures confirmed the diagnosis of invasive fusariosis. This case highlights the importance of early recognition of cutaneous manifestations of fusariosis in immunocompromised pediatric patients and emphasizes the need for multidisciplinary management to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.